Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 3 5 versus CLINIMIX E 5 35 SULFITE FREE W ELECT IN DEXTROSE 35 W CALCIUM IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 3 5 versus CLINIMIX E 5 35 SULFITE FREE W ELECT IN DEXTROSE 35 W CALCIUM IN PLASTIC CONTAINER.
AMINOSYN 3.5% vs CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 3.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, thereby promoting nitrogen balance and tissue repair.
Electrolyte and amino acid supplementation to maintain or restore fluid balance, provide calories from dextrose, and supply essential amino acids for protein synthesis; calcium and other electrolytes support physiological functions.
Intravenous administration of 500 mL to 1000 mL per day as a 3.5% amino acid solution, typically infused at a rate of 1.25-2.5 mL/min (equivalent to 0.25-0.5 g amino acids/kg/day). Dose individualized based on nitrogen requirements and metabolic status.
Intravenous infusion at a rate determined by clinical condition and metabolic requirements. Typical adult initial rate: 100 mL/hr, adjusted based on glucose tolerance and fluid status.
None Documented
None Documented
The plasma half-life of individual amino acids varies; for total amino acid mixture, the terminal elimination half-life is approximately 1-2 hours in patients with normal hepatic and renal function, reflecting rapid uptake into tissues and metabolism. This half-life is clinically relevant for continuous infusion scheduling.
Not applicable as a single entity; amino acids have half-lives ranging from minutes to hours depending on individual amino acid metabolism. Dextrose has a half-life of about 1-2 hours in fasting state, but this formulation is for continuous infusion, so elimination is constant.
Amino acids are primarily eliminated via hepatic metabolism (deamination, transamination) and renal excretion. The renal excretion accounts for approximately 5-10% of the administered dose as unchanged amino acids; the majority is metabolized, and nitrogen is excreted as urea (80-90% of nitrogen) via urine, with minor fecal losses (<5%).
Renal excretion of amino acids and dextrose metabolites; no significant biliary or fecal elimination. Unused amino acids are deaminated and excreted as urea in urine (approximately 80-90% of nitrogen load). Electrolytes are excreted renally.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution